Novocure's PANOVA-3 trial shows TTFields therapy with chemotherapy improves survival in pancreatic cancer, marking a ...

On Monday, NovoCure Ltd (NASDAQ:NVCR) and Zai Lab Limited (NASDAQ:ZLAB) revealed topline data from the Phase 3 PANOVA-3 trial ...

Zai Lab (ZLAB) and Novocure (NVCR) announced that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating ...

Purple Biotech PPBT, a clinical-stage oncology company, reported positive final results from the mid-stage study of its lead ...

Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary ...

Novocure (NVCR) achieves milestone in pancreatic cancer treatment with positive trial results for TTFields therapy, leading ...

Novocure’s positive phase 3 results boost pancreatic cancer treatment prospects. Read why NVCR stock is worth watching with ...

Novocure has cleared a phase 3 clinical study in pancreatic cancer, showing its tumor-treating electric fields could help ...

Novocure plans to file for regulatory approval of TTFields in unresectable, locally advanced pancreatic adenocarcinoma based ...

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer ...

In a Phase III clinical trial, a therapy known as Tumor Treating Fields (TTFields) increased survival for patients whose ...